CY1109297T1 - Συνθεσεις ελεγχομενης απελευθερωσης για ιντερφερονη βασιζομενες σε συμπολυμερη κατα συσταδες pegt/pbt - Google Patents

Συνθεσεις ελεγχομενης απελευθερωσης για ιντερφερονη βασιζομενες σε συμπολυμερη κατα συσταδες pegt/pbt

Info

Publication number
CY1109297T1
CY1109297T1 CY20091100844T CY091100844T CY1109297T1 CY 1109297 T1 CY1109297 T1 CY 1109297T1 CY 20091100844 T CY20091100844 T CY 20091100844T CY 091100844 T CY091100844 T CY 091100844T CY 1109297 T1 CY1109297 T1 CY 1109297T1
Authority
CY
Cyprus
Prior art keywords
composition
pegt
interfero
liberty
compositions
Prior art date
Application number
CY20091100844T
Other languages
English (en)
Inventor
Anne Chantal Bechet
Dijkhuizen-Radersma Riemke Van
Martin Stigter
Jeroen Mattijs Bezemer
Original Assignee
Biolex Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolex Therapeutics, Inc. filed Critical Biolex Therapeutics, Inc.
Publication of CY1109297T1 publication Critical patent/CY1109297T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η εφεύρεση παρουσιάζει φαρμακευτική σύνθεση για την ελεγχόμενη απελευθέρωση σχετικά τοξικών ενεργών ενώσεων, ιδίως για βιοενεργείς πρωτεΐνες από την κατηγορία των ιντερφερονών. Η σύνθεση περιλαμβάνει βιοαποδομήσιμο συμπολυμερές κατά συστάδες δομημένο από πολυ(τερεφθαλική αιθυλενογλυκόλη) (PEGT) και πολυ(τερεφθαλικό βουτυλενεστέρα) (ΡΒΤ). Η σύνθεση παρέχεται σε μορφή ενέσιμων μικροσωματίων, ενέσιμου υγρού το οποίο μπορεί να έχει αυτοπηκτωματικές ιδιότητες, ή στερεού εμφυτεύματος. Η εφεύρεση περαιτέρω παρέχει φαρμακευτικό κιτ που περιλαμβάνει τη σύνθεση, μεθόδους για την παρασκευή της σύνθεσης, και τις φαρμακευτικές χρήσεις που σχετίζονται μ'αυτήν.
CY20091100844T 2005-01-07 2009-08-10 Συνθεσεις ελεγχομενης απελευθερωσης για ιντερφερονη βασιζομενες σε συμπολυμερη κατα συσταδες pegt/pbt CY1109297T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05075043A EP1679065A1 (en) 2005-01-07 2005-01-07 Controlled release compositions for interferon based on PEGT/PBT block copolymers
EP06700417A EP1843749B1 (en) 2005-01-07 2006-01-06 Controlled release compositions for interferon based on pegt/pbt block copolymers

Publications (1)

Publication Number Publication Date
CY1109297T1 true CY1109297T1 (el) 2014-07-02

Family

ID=34937981

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100844T CY1109297T1 (el) 2005-01-07 2009-08-10 Συνθεσεις ελεγχομενης απελευθερωσης για ιντερφερονη βασιζομενες σε συμπολυμερη κατα συσταδες pegt/pbt

Country Status (24)

Country Link
US (3) US7736674B2 (el)
EP (4) EP1679065A1 (el)
JP (2) JP2008526837A (el)
KR (2) KR20070118225A (el)
CN (2) CN101791396A (el)
AT (1) ATE431134T1 (el)
AU (2) AU2006213168B2 (el)
BR (1) BRPI0606514A2 (el)
CA (1) CA2594434A1 (el)
CY (1) CY1109297T1 (el)
DE (1) DE602006006797D1 (el)
DK (1) DK1843749T3 (el)
ES (1) ES2327267T3 (el)
HK (1) HK1152644A1 (el)
HR (1) HRP20090434T1 (el)
IL (2) IL184431A (el)
MX (1) MX2007008293A (el)
PL (1) PL1843749T3 (el)
PT (1) PT1843749E (el)
RS (1) RS51129B (el)
RU (2) RU2409348C2 (el)
SG (1) SG158856A1 (el)
SI (1) SI1843749T1 (el)
WO (1) WO2006085747A1 (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1679065A1 (en) 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
AU2008279087A1 (en) * 2007-07-25 2009-01-29 Biolex Therapeutics, Inc. Controlled release interferon drug products and treatment of HCV infection using same
EP2055299A1 (en) * 2007-10-23 2009-05-06 Koninklijke Philips Electronics N.V. Methods for preparing polymer microparticles
WO2009053885A2 (en) 2007-10-23 2009-04-30 Koninklijke Philips Electronics N.V. Methods for preparing polymer microparticles
AU2009265170A1 (en) * 2008-06-30 2010-01-07 Silenseed Ltd Methods, compositions and systems for local delivery of drugs
CA2753001A1 (en) 2009-03-05 2010-09-10 Ascendis Pharma As Interferon alpha carrier prodrugs
BR112013024655A2 (pt) * 2011-03-25 2016-12-20 Selecta Biosciences Inc nanotransportadores sintéticos para liberação mediada de modo osmótico
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8853176B2 (en) 2011-10-21 2014-10-07 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
WO2016046817A1 (en) 2014-09-24 2016-03-31 Vital Beverages Global Inc. Compositions and methods for selective gi tract delivery
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
EP3996660A1 (en) 2019-07-12 2022-05-18 Basf Se Process for producing microparticles laden with a volatile organic active

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE634668A (el) * 1962-07-11
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5192743A (en) * 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
JPH07505813A (ja) 1992-04-24 1995-06-29 オステオテク，インコーポレイテッド 組織癒着予防装置
US5711968A (en) * 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
ES2110573T3 (es) 1992-08-07 1998-02-16 Takeda Chemical Industries Ltd Produccion de microcapsulas de farmacos solubles en agua.
US5643605A (en) 1993-10-25 1997-07-01 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
US6117455A (en) 1994-09-30 2000-09-12 Takeda Chemical Industries, Ltd. Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
US5612052A (en) 1995-04-13 1997-03-18 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
CA2238829A1 (en) 1995-11-30 1997-06-05 Board Of Regents, The University Of Texas System Methods and compositions for the diagnosis and treatment of cancer
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
US5980948A (en) * 1996-08-16 1999-11-09 Osteotech, Inc. Polyetherester copolymers as drug delivery matrices
DE69840169D1 (de) 1997-02-27 2008-12-11 Novartis Ag Arzneimittel zubereitung enthaltend 2-amino-2-ä2-(4-octylphenyl)ethylüpropane-1,3-diol, ein lecithin und ein saccharid
DK0975334T3 (da) * 1997-04-17 2004-01-19 Amgen Inc Biologisk nedbrydelige mikropartikler til langvarig frigivelse af terapeutiske midler
AR012448A1 (es) 1997-04-18 2000-10-18 Ipsen Pharma Biotech Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
US6531154B1 (en) 1997-06-10 2003-03-11 Brown University Research Foundation Modulated release from biocompatible polymers
WO1999021578A1 (en) * 1997-10-24 1999-05-06 Eli Lilly And Company Insoluble insulin compositions
US6270802B1 (en) 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
EP1145713A4 (en) * 1999-01-12 2003-08-06 Kyowa Hakko Kogyo Kk Telomerase inhibitors
US6204308B1 (en) 1999-03-01 2001-03-20 Novartis Ag Organic compounds
US20030206928A1 (en) * 1999-04-07 2003-11-06 Pertti Tormala Bioactive, bioabsorbable surgical polyethylene glycol and polybutylene terephtalate copolymer composites and devices
US6291013B1 (en) 1999-05-03 2001-09-18 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
HUP0202880A3 (en) 1999-07-15 2003-04-28 Takeda Chemical Industries Ltd Sustained release compositions, process for producing the same and use thereof
EP1090928B1 (en) 1999-09-30 2004-05-26 Chienna B.V. Polymers loaded with bioactive agents
US6465425B1 (en) 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6479065B2 (en) 2000-08-10 2002-11-12 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
US6471995B1 (en) 2000-09-27 2002-10-29 Alkermes Controlled Therapeutics, Inc. Ii Apparatus and method for preparing microparticles using liquid-liquid extraction
JP4557409B2 (ja) * 2000-11-13 2010-10-06 日東電工株式会社 多孔質ポリイミドの製造方法及び多孔質ポリイミド
CA2431285A1 (en) 2000-12-13 2002-06-20 Merckle Gmbh Microparticles with an improved release profile and method for the production thereof
CA2433037C (en) 2000-12-28 2010-12-21 Takeda Chemical Industries, Ltd. Sustained-release preparation
RU2191012C1 (ru) 2001-06-20 2002-10-20 Научно-исследовательский испытательный центр (медико-биологической защиты) Государственного научно-исследовательского испытательного института военной медицины МО РФ Глазные капли для лечения эндотелиально-эпителиальной дистрофии роговицы
JP2005508220A (ja) 2001-10-24 2005-03-31 パーリ・ゲーエムベーハー 薬用組成物調製用具
CA2466998A1 (en) * 2001-11-12 2003-05-22 Alkermes Controlled Therapeutics, Inc. Biocompatible polymer blends and uses thereof
TWI252111B (en) 2001-12-14 2006-04-01 Solvay Pharm Gmbh Matrix film tablet with controlled release of a natural mixture of conjugated estrogens
KR100994658B1 (ko) 2001-12-26 2010-11-16 다케다 야쿠힌 고교 가부시키가이샤 신규 마이크로스피어 및 이들의 제조 방법
WO2004000363A1 (ja) 2002-06-25 2003-12-31 Takeda Pharmaceutical Company Limited 徐放性組成物の製造方法
EP1651136B1 (en) 2003-07-15 2017-03-08 Evonik Corporation Method for the preparation of controlled release formulations
ES2536235T3 (es) 2004-04-15 2015-05-21 Alkermes Pharma Ireland Limited Dispositivo polimérico de liberación prolongada
EP1679065A1 (en) 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers

Also Published As

Publication number Publication date
KR101354521B1 (ko) 2014-01-22
PT1843749E (pt) 2009-08-17
IL184431A (en) 2012-03-29
US8163307B2 (en) 2012-04-24
PL1843749T3 (pl) 2009-10-30
JP4887542B2 (ja) 2012-02-29
EP1886668A1 (en) 2008-02-13
ES2327267T3 (es) 2009-10-27
CN101137349A (zh) 2008-03-05
RU2409348C2 (ru) 2011-01-20
AU2006213168B2 (en) 2011-09-15
EP1679065A1 (en) 2006-07-12
AU2010224413B2 (en) 2012-03-22
RS51129B (sr) 2010-10-31
EP2266535A2 (en) 2010-12-29
IL208175A0 (en) 2010-12-30
DE602006006797D1 (de) 2009-06-25
CN101791396A (zh) 2010-08-04
KR20070118225A (ko) 2007-12-14
EP1886668B1 (en) 2012-11-14
SI1843749T1 (sl) 2009-10-31
EP2266535A3 (en) 2011-06-15
EP1843749B1 (en) 2009-05-13
US7867518B2 (en) 2011-01-11
JP2008526837A (ja) 2008-07-24
CN101137349B (zh) 2013-01-02
ATE431134T1 (de) 2009-05-15
RU2007130090A (ru) 2009-02-20
DK1843749T3 (da) 2009-09-07
CA2594434A1 (en) 2006-08-17
AU2010224413A1 (en) 2010-10-14
JP2011016836A (ja) 2011-01-27
BRPI0606514A2 (pt) 2010-01-19
EP1843749A1 (en) 2007-10-17
EP2266535B1 (en) 2013-03-06
AU2006213168A1 (en) 2006-08-17
HRP20090434T1 (hr) 2009-09-30
US20090226532A1 (en) 2009-09-10
SG158856A1 (en) 2010-02-26
HK1152644A1 (en) 2012-03-09
US20100074868A1 (en) 2010-03-25
RU2010138739A (ru) 2012-03-27
US7736674B2 (en) 2010-06-15
US20080008733A1 (en) 2008-01-10
KR20100109983A (ko) 2010-10-11
IL184431A0 (en) 2007-10-31
MX2007008293A (es) 2007-12-07
WO2006085747A1 (en) 2006-08-17

Similar Documents

Publication Publication Date Title
CY1109297T1 (el) Συνθεσεις ελεγχομενης απελευθερωσης για ιντερφερονη βασιζομενες σε συμπολυμερη κατα συσταδες pegt/pbt
ES2535084T3 (es) Proteínas N-glicosiladas recombinantes procedentes de células procariotas
BRPI0513405A (pt) tienopirimidinas úteis como inibidores de aurora quinase
WO2007050387A3 (en) Keratin bioceramic compositions
WO2007043048A3 (en) Self-assembled fmoc-ff hydrogels
ATE544802T1 (de) Polyglutamat-aminosäure-konjugate und verfahren
CL2007002327A1 (es) Compuestos derivados de fenil-imidazol sustituido; composicion farmaceutica; y uso en el tratamiento del vhc.
ECSP045191A (es) "nuevos péptidos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c"
AR055897A1 (es) Composiciones de poliester que comprenden cantidades minimas de ciclobutanodiol
EA201100158A1 (ru) Антагонисты активина-actriia и их применение для стимулирования роста кости
BRPI0606687A2 (pt) composições nutracêuticas
WO2007127440A3 (en) Heterofunctional poly(ethylene glycol) containing acid-labile amino protecting groups and uses thereof
EA200800927A1 (ru) КОМПОЗИЦИЯ ДЛЯ АЭРОЗОЛЬНОЙ ИНГАЛЯЦИИ β-АГОНИСТОВ
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
EA200601596A1 (ru) Улучшенный состав 6-меркаптопурина
ATE446763T1 (de) Pharmazeutische formulierung zur behandlung von osteoarthritis mit clodronsäure und hyaluronsäure
AU2003251728A8 (en) Placental growth factor as a target for the treatment of osteoporosis
DE602004025689D1 (de) Antivirale mittel zur behandlung, kontrolle und prävention von infektionen durch coronaviren
BRPI0508895A (pt) formas polimorficas e amorfa de {2-flúor-5-[3-((e)-2-piridn-2-il-vinil)-1h-indazol-6-ilamin]- fenil}-amida de ácido 2,5-dimetil-2h-pirazol-3-carboxìlico
TW200716178A (en) Macromolecular conjugates of bone morphogenetic protein-7
RU2006144370A (ru) Способ профилактики послеоперационного остеомиелита
EA200900266A1 (ru) КОМПОЗИЦИЯ ДЛЯ АЭРОЗОЛЬНОЙ ИНГАЛЯЦИИ β-АГОНИСТОВ
DE102005021846A8 (de) Verfahren zur Herstellung von Albumin-Konjugaten mit einem Röntgenkontrastmittel als Wirkstoff
RU2005138252A (ru) Композиции на основе акульего жира